Diabetes research and clinical practice
-
Diabetes Res. Clin. Pract. · Oct 2014
Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
We evaluated the patterns and determinants that influence the selection, timing and duration of first-line antihyperglycaemic drug (AHD) treatment in patients with type 2 diabetes in Germany, focusing specifically on treatment-naive AHD initiators. ⋯ The majority of patients were not started on AHD therapy within 5 years after enrollment. In line with recent therapy guidelines, current first-line antihyperglycaemic treatment was increasingly based on metformin. AHD initiators started on sulfonylurea were generally more advanced in their disease and were started later on primary pharmacotherapy.